Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.77
Dollar change
+0.03
Percentage change
1.09
%
IndexRUT P/E- EPS (ttm)-0.87 Insider Own5.05% Shs Outstand150.29M Perf Week-9.18%
Market Cap416.41M Forward P/E- EPS next Y-0.06 Insider Trans4.26% Shs Float142.74M Perf Month2.59%
Income-110.56M PEG- EPS next Q-0.07 Inst Own71.21% Short Float17.81% Perf Quarter65.87%
Sales127.04M P/S3.28 EPS this Y73.33% Inst Trans7.14% Short Ratio8.27 Perf Half Y179.54%
Book/sh-0.23 P/B- EPS next Y70.31% ROA-46.70% Short Interest25.43M Perf Year72.05%
Cash/sh0.53 P/C5.18 EPS next 5Y47.50% ROE-2408.88% 52W Range0.50 - 3.22 Perf YTD62.94%
Dividend Est.- P/FCF- EPS past 5Y20.01% ROI-77.54% 52W High-13.98% Beta1.68
Dividend TTM- Quick Ratio1.84 Sales past 5Y17.85% Gross Margin48.75% 52W Low454.00% ATR (14)0.22
Dividend Ex-Date- Current Ratio2.37 EPS Y/Y TTM49.36% Oper. Margin-87.07% RSI (14)50.85 Volatility6.65% 8.28%
Employees126 Debt/Eq- Sales Y/Y TTM17.99% Profit Margin-87.02% Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q57.19% Payout- Rel Volume0.36 Prev Close2.74
Sales Surprise9.63% EPS Surprise54.49% Sales Q/Q14.00% EarningsMar 12 AMC Avg Volume3.08M Price2.77
SMA200.08% SMA506.24% SMA20069.60% Trades Volume1,104,457 Change1.09%
Date Action Analyst Rating Change Price Target Change
Mar-13-24Reiterated Needham Buy $4 → $5
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
Sep-27-17Initiated Northland Capital Outperform $40
Feb-27-17Initiated Needham Buy $28
Mar-28-24 04:05PM
Mar-13-24 09:19AM
07:04AM
Mar-12-24 06:00PM
05:33PM
04:34PM Loading…
04:34PM
04:05PM
Mar-07-24 09:15AM
Feb-28-24 08:00AM
Feb-23-24 11:56AM
Feb-06-24 12:00PM
Jan-25-24 06:44AM
Jan-24-24 01:47PM
Jan-23-24 08:00PM
Jan-15-24 04:51PM
09:55AM Loading…
09:55AM
Jan-07-24 05:00PM
Dec-10-23 12:23PM
Dec-06-23 11:55AM
Nov-28-23 07:33PM
Nov-15-23 10:17AM
08:51AM
08:46AM
Nov-14-23 06:00PM
04:17PM
04:05PM
Nov-07-23 04:05PM
Aug-24-23 09:29AM
Aug-15-23 01:30PM
12:48PM
09:47AM Loading…
09:47AM
Aug-14-23 04:29PM
04:05PM
Aug-07-23 04:05PM
10:50AM
Jul-26-23 01:30PM
Jul-24-23 09:02AM
09:00AM
Jun-23-23 04:05PM
Jun-12-23 09:00AM
May-11-23 05:15PM
04:12PM
04:01PM
May-05-23 12:28PM
Apr-20-23 11:45AM
09:00AM
Apr-17-23 04:05PM
Apr-06-23 03:42PM
02:01PM
Apr-03-23 09:00AM
Mar-27-23 07:12AM
Mar-24-23 06:43AM
Mar-23-23 09:28PM
05:35PM
04:05PM
Mar-13-23 09:00AM
Mar-10-23 04:05PM
Mar-06-23 09:00AM
Feb-27-23 04:30PM
Feb-22-23 09:00AM
Jan-30-23 05:54AM
Jan-09-23 08:30AM
Dec-29-22 09:45AM
09:00AM
Dec-28-22 12:32PM
Dec-20-22 03:41PM
Nov-21-22 04:05PM
Nov-15-22 10:14PM
Nov-10-22 05:44AM
Nov-09-22 01:15PM
Nov-08-22 06:25PM
04:05PM
Nov-04-22 11:48AM
Nov-01-22 04:05PM
Sep-26-22 09:45AM
Sep-23-22 09:19AM
07:30AM
Sep-19-22 06:42AM
Sep-16-22 02:49PM
Sep-12-22 07:37AM
Aug-23-22 12:00PM
Aug-15-22 09:55AM
Aug-09-22 02:10PM
09:15AM
08:01AM
08:00AM
Aug-02-22 04:05PM
Jul-21-22 06:32AM
Jul-18-22 06:00PM
Jun-30-22 08:41AM
08:30AM
Jun-14-22 08:30AM
May-26-22 04:05PM
May-16-22 04:05PM
May-09-22 06:45PM
04:05PM
May-03-22 04:05PM
Apr-05-22 04:05PM
Mar-28-22 03:14PM
Mar-25-22 08:30AM
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forbes William PEVP, Chief Development OfficerNov 17 '23Buy1.0925,00027,25079,000Nov 21 12:19 PM
Collard Craig AChief Executive OfficerNov 16 '23Buy0.92150,000137,970186,496Nov 17 12:37 PM
Duarte IraEVP, Chief Financial OfficerNov 16 '23Buy0.8985,00075,59985,000Nov 17 12:36 PM
Forbes William PEVP, Chief Development OfficerNov 16 '23Buy0.9450,00046,99554,000Nov 20 10:07 AM
Morgan AdamDirectorJul 21 '23Buy1.372,486,7443,406,8396,986,744Jul 25 04:22 PM
Last Close
Mar 28 04:00PM ET
1.18
Dollar change
+0.01
Percentage change
0.85
%
GOSS Gossamer Bio Inc weekly Stock Chart
Index- P/E- EPS (ttm)-1.38 Insider Own16.30% Shs Outstand225.41M Perf Week-10.61%
Market Cap266.18M Forward P/E- EPS next Y-0.69 Insider Trans0.51% Shs Float188.82M Perf Month-13.24%
Income-179.82M PEG- EPS next Q-0.18 Inst Own79.44% Short Float5.87% Perf Quarter34.12%
Sales0.00M P/S- EPS this Y36.87% Inst Trans11.72% Short Ratio10.18 Perf Half Y49.03%
Book/sh0.28 P/B4.24 EPS next Y6.90% ROA-61.54% Short Interest11.09M Perf Year-6.35%
Cash/sh1.31 P/C0.90 EPS next 5Y5.20% ROE-480.50% 52W Range0.45 - 1.88 Perf YTD29.32%
Dividend Est.- P/FCF- EPS past 5Y11.99% ROI-69.08% 52W High-37.23% Beta1.70
Dividend TTM- Quick Ratio5.94 Sales past 5Y0.00% Gross Margin- 52W Low160.77% ATR (14)0.11
Dividend Ex-Date- Current Ratio5.94 EPS Y/Y TTM49.48% Oper. Margin0.00% RSI (14)42.05 Volatility6.67% 8.46%
Employees135 Debt/Eq3.38 Sales Y/Y TTM- Profit Margin- Recom1.80 Target Price5.97
Option/ShortYes / Yes LT Debt/Eq3.15 EPS Q/Q63.89% Payout- Rel Volume0.98 Prev Close1.17
Sales Surprise- EPS Surprise-0.82% Sales Q/Q- EarningsMar 05 BMO Avg Volume1.09M Price1.18
SMA20-14.18% SMA504.50% SMA20016.12% Trades Volume1,068,341 Change0.85%
Date Action Analyst Rating Change Price Target Change
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Sep-21-22Initiated JP Morgan Neutral $17
Sep-19-22Initiated Wedbush Outperform $24
Apr-18-22Initiated Raymond James Outperform $19
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM Loading…
07:40AM
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
08:11AM Loading…
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM Loading…
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Oct-24-22 08:30AM
Aug-29-22 08:11AM
Aug-09-22 08:01AM
Jul-21-22 06:21PM
Jul-20-22 11:33AM
Jul-19-22 12:00PM
09:46AM
Jul-18-22 09:55AM
Jul-13-22 07:15AM
Jun-09-22 08:30AM
May-26-22 09:55AM
May-23-22 09:55AM
May-10-22 04:01PM
May-06-22 12:20PM
Apr-25-22 07:29AM
Mar-03-22 04:01PM
Feb-28-22 07:01AM
Jan-02-22 08:47AM
Nov-08-21 04:01PM
Nov-02-21 04:01PM
Oct-11-21 08:36AM
Oct-07-21 04:01PM
Oct-03-21 10:45AM
Sep-21-21 08:31AM
Aug-09-21 04:01PM
Aug-02-21 04:01PM
Jul-21-21 05:16AM
Jul-17-21 05:47AM
Jul-07-21 07:01AM
Jun-21-21 04:01PM
Jun-14-21 04:01PM
May-06-21 07:31AM
Apr-20-21 07:50AM
Apr-16-21 07:55AM
Feb-25-21 07:31AM
Feb-19-21 08:01AM
Feb-04-21 07:05AM
Jan-18-21 03:05AM
Dec-19-20 03:54PM
Dec-11-20 05:00PM
Dec-07-20 07:03AM
Nov-16-20 07:01AM
Nov-10-20 04:01PM
02:30PM
08:00AM
Nov-06-20 07:07AM
07:03AM
Oct-13-20 03:02PM
07:04AM
Oct-12-20 08:07AM
Oct-09-20 08:01AM
Sep-30-20 08:38AM
Sep-10-20 07:07AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hasnain FaheemPresident & CEOMar 27 '24Sale1.1623,17226,773120,293Mar 28 06:01 PM
Giraudo BryanCOO/CFOMar 27 '24Sale1.166,4307,43192,737Mar 28 06:05 PM
Christian WaageEVP, Tech Ops and AdminMar 27 '24Sale1.166,4307,430585,934Mar 28 06:16 PM
Peterson CarynEVP, Regulatory AffairsMar 18 '24Sale1.334,0185,34349,833Mar 19 06:50 PM
Aranda RichardChief Medical OfficerMar 18 '24Sale1.334,0185,342198,799Mar 19 06:50 PM
Milligan SandraDirectorNov 15 '23Buy0.7932,00025,21332,000Nov 17 04:01 PM
Giraudo BryanCOO/CFONov 13 '23Buy0.56200,000112,880380,010Nov 14 06:24 PM
Aranda RichardChief Medical OfficerJun 22 '23Sale1.291,8142,340197,574Jun 26 04:01 PM
Giraudo BryanCOO/CFOApr 04 '23Buy1.0255,00056,094125,990Apr 05 04:26 PM